Overview

Retro Biosciences focuses on extending healthy human lifespan by ten years through the development of therapeutics that target the cellular mechanisms of aging. The company addresses the root causes of age-related diseases, which are responsible for a significant portion of healthcare costs. Its product development is organized into three main programs: cellular reprogramming, plasma-inspired therapeutics, and autophagy, each at different stages of progress. Retro Biosciences utilizes advanced technologies like single-cell multi-omics and computational biology to enhance its research and development efforts. Unlike many competitors, Retro Biosciences has secured substantial funding of $180 million to support its operations and aims to achieve clinical applications for its therapeutic candidates. The company's goal is to reduce healthcare costs associated with aging and improve the quality of life for individuals as they age.

Simplify's Take

What believers are saying

• Retro Biosciences secured $1 billion in funding to extend human lifespan.
• Partnership with Multiply Labs enhances cell therapy manufacturing efficiency.
• Collaboration with OpenAI improves stem cell production through AI models.

What critics are saying

• Ethical concerns over longevity research may lead to regulatory scrutiny.
• AI development may outpace regulatory frameworks, posing compliance challenges.
• Technical challenges in automated cell therapy manufacturing could delay timelines.

What makes Retro Biosciences unique

• Retro Biosciences focuses on cellular reprogramming, autophagy, and plasma-inspired therapeutics.
• The company aims to extend healthy human lifespan by ten years.
• Retro Biosciences employs advanced technologies like single-cell multi-omics and computational biology.

Help us improve and share your feedback! Did you find this helpful?

YesNo